Insemination

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Retrieved on: 
星期二, 五月 7, 2024

With the addition of new team members to its commercial team in key strategic geographical locations, Femasys is poised to fully initiate its strategic initiatives and execute on its delivery of innovative, accessible options to impact women’s healthcare.

Key Points: 
  • With the addition of new team members to its commercial team in key strategic geographical locations, Femasys is poised to fully initiate its strategic initiatives and execute on its delivery of innovative, accessible options to impact women’s healthcare.
  • The newly appointed team brings together seasoned professionals with a wealth of commercial experience across various sectors of the healthcare industry.
  • Their collective expertise plays a pivotal role in driving Femasys' commercial efforts forward to realize the Company’s strategic vision, with initial emphasis on the Company’s infertility portfolio, led by the FemaSeed® product.
  • The 2024 ACOG meeting presents an ideal opportunity for Femasys to showcase the strength of its initial commercial team and its commitment to shaping the future of women's healthcare.

National Women’s Law Center and Law Firm Emery Celli Brinckerhoff Abady Ward & Maazel, LLP Announce Settlement of Class Action Lawsuit Against Aetna Over LGBTQ+ Fertility Coverage

Retrieved on: 
星期五, 五月 3, 2024

v. Aetna , filed in September 2021, the plaintiffs challenged Aetna’s definition of infertility, alleging it led to unequal insurance coverage treatment for LGBTQ+ couples.

Key Points: 
  • v. Aetna , filed in September 2021, the plaintiffs challenged Aetna’s definition of infertility, alleging it led to unequal insurance coverage treatment for LGBTQ+ couples.
  • Aetna will re-process eligible insurance claims to reimburse class members for their out-of-pocket artificial insemination cycles, up to the plan limits.
  • Aetna will also separately pay all the costs of the administrator and special master who will allocate the common fund.
  • If you believe you are in the class of individuals covered by this settlement, please visit this page or contact: 1-800-205-6861.

San Diego Zoo Wildlife Alliance Leaders Visit China; Meet Giant Panda Pair To Be Cared For By San Diego Zoo

Retrieved on: 
星期一, 四月 29, 2024

SAN DIEGO, April 29, 2024 /PRNewswire/ -- San Diego Zoo Wildlife Alliance conservation and care team leaders recently visited China and met Yun Chuan (pronounced yoon chu-an) and Xin Bao (pronounced sing bao) the two giant pandas to be cared for by San Diego Zoo.

Key Points: 
  • SAN DIEGO, April 29, 2024 /PRNewswire/ -- San Diego Zoo Wildlife Alliance conservation and care team leaders recently visited China and met Yun Chuan (pronounced yoon chu-an) and Xin Bao (pronounced sing bao) the two giant pandas to be cared for by San Diego Zoo.
  • "Yun Chuan's lineage has deep connections to the San Diego Zoo and we're excited by the prospect of caring for them."
  • The first character of his name, "Yun," is a nod to his grandmother Bai Yun, who thrived at San Diego Zoo for 23 years.
  • San Diego Zoo Wildlife Alliance leaders were in China meeting with conservation partners from China Wildlife Conservation Association on prospective research programs to protect and conserve giant pandas and their habitat.

Survey Reveals Women Trying to Get Pregnant Report Loneliness and Self-Blame

Retrieved on: 
星期四, 五月 2, 2024

A new survey commissioned by First Response™ in collaboration with RESOLVE: The National Infertility Association shows that women report feeling lonely, blame themselves and find misinformation as they are trying to get pregnant.

Key Points: 
  • A new survey commissioned by First Response™ in collaboration with RESOLVE: The National Infertility Association shows that women report feeling lonely, blame themselves and find misinformation as they are trying to get pregnant.
  • More than two-thirds of women trying to conceive (68%) are worried about their ability to become pregnant and one-third were concerned that not being able to get pregnant would be their fault (32%).
  • Almost 2 in 5 women who are trying (38%) wish they knew how much conflicting information there was before they began attempting to get pregnant.
  • 93% of women believe at least three misconceptions about trying to get pregnant when given a knowledge test about common facts regarding pregnancy.

African wild dogs will soon have their own sperm bank – how artificial breeding will help them survive

Retrieved on: 
星期三, 四月 10, 2024

They’ve now decided to freeze sperm from as many genetically diverse male African wild dogs as possible and use this to artificially inseminate female African wild dogs for the first time.

Key Points: 
  • They’ve now decided to freeze sperm from as many genetically diverse male African wild dogs as possible and use this to artificially inseminate female African wild dogs for the first time.
  • Reproductive and molecular biologist Damien Paris explains why artificial breeding is the best and most economical way to ensure that genetically diverse wild dogs live on.

Why is the African wild dog in danger?

  • They are highly efficient pack hunters but need large home ranges to survive and avoid competitors like lions.
  • The problem is that most of the remaining habitats are so small and fragmented that they can’t support large populations anymore.
  • Usually, when wild dogs are subadults (around two years old) they move far away and form their own pack.

How can genetic diversity help the African wild dog survive?

  • Those diseases can spread rapidly among wild dogs and decimate a pack, which is about five to 20 dogs.
  • In 2017, canine distemper virus completely wiped out 21 out of 22 packs of wild dogs in Laikipia County, Kenya in less than four weeks.
  • We plan to use sperm freezing and artificial insemination to help distribute genetic diversity between isolated populations.

What conservation methods have been used before?

  • To increase genetic diversity, African wild dogs have been translocated (moved) across South Africa since 1998.
  • Over several weeks, they form a new genetically mixed pack that is released into the wild.
  • A whole population of wild dogs could be lost with the next disease outbreak.

How will sperm freezing and artificial insemination help?

  • Our back-up plan against disease outbreaks is to create a bank of African wild dog sperm from multiple males.
  • Sperm frozen in liquid nitrogen tanks at very cold temperatures can last 50 or 100 years and still produce offspring.
  • We recently improved the freezing technique so African wild dog sperm are now able to swim and survive for eight hours after being thawed.
  • We plan to build a consortium so that we can have multiple sperm banks throughout South Africa as back-ups.

Will this be very expensive?

  • Some recent modelling in other species found that the hybrid approach was between seven and 84 times cheaper than the natural breeding approach.
  • This is because it needed 13-100 times fewer animals to maintain 90% genetic diversity in the population over a 100-year period.


Damien Boyd Bertrand Paul Paris receives funding from Morris Animal Foundation, Roger Willliams Park
Zoo and Fresno Chaffee Zoo. He is affiliated with James Cook University, the Institute for Breeding Rare and Endangered African Mammals, and is a Visiting Fellow of the Mammal Research Institute.

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Retrieved on: 
星期四, 三月 28, 2024

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update.

Key Points: 
  • ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update.
  • Following FDA clearance of FemaSeed, the Company’s revolutionary approach to artificial insemination, Femasys announced completion of enrollment in pivotal trial in support of commercial launch
    Appointed Richard Spector as Chief Commercial Officer and James Liu, M.D.
  • Notably, the majority of women who became pregnant did so after the first FemaSeed procedure,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “Our focus is now on executing on commercialization of FemaSeed and our other available products, as well as advancing the clinical pivotal trial for FemBloc.

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Retrieved on: 
星期三, 三月 20, 2024

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces topline data from its FemaSeed Localized Directional Insemination for artificial insemination pivotal trial (NCT04968847). The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility. FemaSeed, engineered to enhance fertilization by precisely delivering sperm into the fallopian tube, the site of conception, demonstrated 24% of women became pregnant after FemaSeed with severe male factor (1 million to 20 million total motile sperm count (TMSC)). In contrast, a 6.7% pregnancy rate by cycle was described in the literature for intrauterine insemination (IUI) with male factor (greater than 1 million TMSC).1 Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The poor IUI pregnancy rates for this infertility segment usually necessitates assisted reproductive approaches, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Key Points: 
  • The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility.
  • “These impressive topline results for our now FDA-cleared FemaSeed, demonstrate significant progress in the treatment of infertility, while confirming its safety profile.
  • “The pivotal trial amassed substantial prospective data in support of the safety and efficacy of FemaSeed as a groundbreaking advancement in artificial insemination.
  • The pivotal trial was concluded prior to completing full enrollment due to Femasys receiving FDA clearance for FemaSeed under the 510(k) pathway in September 2023.

San Diego Zoo Wildlife Alliance and China Wildlife Conservation Association Sign a New Cooperative Agreement for Giant Panda Collaboration

Retrieved on: 
星期四, 二月 22, 2024

SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- San Diego Zoo Wildlife Alliance (SDZWA) took an important step forward in having giant pandas return to the San Diego Zoo by signing a cooperative agreement with China Wildlife Conservation Association and filing a permit application with the U.S. Fish and Wildlife Service.

Key Points: 
  • SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- San Diego Zoo Wildlife Alliance (SDZWA) took an important step forward in having giant pandas return to the San Diego Zoo by signing a cooperative agreement with China Wildlife Conservation Association and filing a permit application with the U.S.
  • SDZWA has a nearly 30-year conservation partnership with research collaborators in China focused on protecting and recovering giant pandas.
  • As such, San Diego Zoo Wildlife Alliance is taking important steps to ensure we are prepared for a potential return.
  • San Diego Zoo Wildlife Alliance is uniquely positioned to collaborate toward a shared goal of creating a sustainable future for giant pandas."

PherDal, the First and Only Sterile At-Home Insemination Kit, Awarded FDA Clearance; Now Accepting Pre-Orders

Retrieved on: 
星期二, 一月 16, 2024

DIXON, Ill., Jan. 16, 2024 /PRNewswire-PRWeb/ -- PherDal Fertility Science, Inc., creators of the first and only sterile, at-home insemination kit, is now accepting pre-orders of its intravaginal insemination (IVI) device, following FDA class II clearance. Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.

Key Points: 
  • Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.
  • Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.
  • Each PherDal Kit includes three (3) sterile syringes and three (3) sterile collection cups to make at-home insemination as sterile, safe and accessible as possible.
  • My husband, a mechanical engineer, and I invented the PherDal Kit, which successfully conceived our daughter with the second use.

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Retrieved on: 
星期四, 十一月 30, 2023

Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®.

Key Points: 
  • Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®.
  • “With an exciting product pipeline and a culture focused on execution of the development and commercialization of differentiated women’s health procedures, Femasys stands apart in the industry,” said Dr. Liu.
  • He also served as the Division head, Reproductive Endocrinology and Infertility at the University of Cincinnati.
  • Ms. Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys, commented on the appointment of Dr. Liu, stating, “It is a great pleasure to welcome Dr. James Liu to Femasys as the Company’s next chief medical officer.